Andrey Zaritskey
Overview
Explore the profile of Andrey Zaritskey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bogdanov K, Kudryavtseva E, Fomicheva Y, Churkina I, Lomaia E, Girshova L, et al.
Pathophysiology
. 2023 Aug;
30(3):296-313.
PMID: 37606386
Mutations in the gene not only lead to abnormalities in its structure and function, but also affect the expression of other genes involved in leukemogenesis. This study evaluated the expression...
2.
Smirnov S, Petukhov A, Levchuk K, Kulemzin S, Staliarova A, Lepik K, et al.
Front Immunol
. 2022 Jan;
12:780145.
PMID: 34975869
Despite the outstanding results of treatment using autologous chimeric antigen receptor T cells (CAR-T cells) in hematological malignancies, this approach is endowed with several constraints. In particular, profound lymphopenia in...
3.
Passamonti F, Gupta V, Martino B, Foltz L, Zaritskey A, Al-Ali H, et al.
Hematol Oncol
. 2021 Jul;
39(4):558-566.
PMID: 34224180
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, has demonstrated durable improvements in patients with myelofibrosis. In this analysis of the Phase 3b JUMP study, which included patients aged ≥18 years...
4.
Shatilova A, Girshova L, Zaytsev D, Budaeva I, Mirolyubova Y, Ryzhkova D, et al.
BMC Womens Health
. 2021 May;
21(1):184.
PMID: 33933047
Background: Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An...
5.
Pfirrmann M, Clark R, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al.
Leukemia
. 2020 Jul;
34(8):2138-2149.
PMID: 32601376
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results. For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used. Our...
6.
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
Zaytsev D, Girshova L, Ivanov V, Budaeva I, Motorin D, Badaev R, et al.
Biology (Basel)
. 2020 Feb;
9(2).
PMID: 32050707
Objectives: To the best of our knowledge, data from Gemtuzumab ozogamicin in Acute Myeloid Leukemia (AML) patients with failure of organ functions and poor performance status are extremely lacking. Moreover,...
7.
Al-Ali H, Griesshammer M, Foltz L, Palumbo G, Martino B, Palandri F, et al.
Br J Haematol
. 2020 Feb;
189(5):888-903.
PMID: 32017044
Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large (N = 2233), phase 3b, expanded-access study...
8.
Dinikina Y, Belogurova M, Zaritskey A, Govorov I, Tsibizova V, Gamzatova Z, et al.
J Matern Fetal Neonatal Med
. 2019 Sep;
34(14):2391-2398.
PMID: 31500478
In children with cancer, the issues related to the quality of life are becoming increasingly important together with the improvement of survival rates. This creates an entirely new challenge -...
9.
Bosch F, Cantin G, Cortelezzi A, Knauf W, Tiab M, Turgut M, et al.
Leukemia
. 2019 Aug;
34(2):441-450.
PMID: 31455851
GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (CLL). We report...
10.
Titov A, Petukhov A, Staliarova A, Motorin D, Bulatov E, Shuvalov O, et al.
Cell Death Dis
. 2018 Sep;
9(9):897.
PMID: 30181581
Currently, immunotherapy is attracting a lot of attention and may potentially become a leading approach in the treatment of cancer. One emerging therapeutic, the chimeric-antigen receptor T-cell adoptive immunotherapy (CAR-T)...